{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T23:14:47Z","timestamp":1767395687568,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ad.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T08:46:57Z","timestamp":1427618817000},"page":"483-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factores predictores de respuesta y revisi\u00f3n de la toxicidad cut\u00e1nea de cetuximab y panitumumab en 116 pacientes"],"prefix":"10.1016","volume":"106","author":[{"given":"A.","family":"Jaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guti\u00e9rrez-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00f3pez-Pesta\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"del Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zubizarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vildosola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sarasqueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tuneu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2015.01.006_bib0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2012.05.001","article-title":"Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations","volume":"85","author":"Custodio","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ad.2015.01.006_bib0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0001-7310(06)73407-X","article-title":"Efectos cut\u00e1neos de los inhibidores del receptor del factor de crecimiento epid\u00e9rmico","volume":"97","author":"Guhl","year":"2006","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.01.006_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","article-title":"The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: A systematic review and meta-analysis of published trials","volume":"8","author":"Petrelli","year":"2013","journal-title":"Target Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/1078-0432.CCR-09-1928","article-title":"Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment","volume":"16","author":"Klinghammer","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2015.01.006_bib0175","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/era.13.30","article-title":"Dermatologic adverse events associated with afatinib: An oral ErbB family blocker","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.ad.2015.01.006_bib0180","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.ad.2015.01.006_bib0185","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"Stintzing","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0195","first-page":"62","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0200","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: Observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.ad.2015.01.006_bib0210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/exd.12510","article-title":"Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients","volume":"23","author":"Jaka","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2015.01.006_bib0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12029-013-9485-7","article-title":"Skin rash during cetuximab treatment in advanced colorectal cancer: Is age a clinical predictor","volume":"44","author":"Giuliani","year":"2013","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0220","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0225","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrclinonc.2012.142","article-title":"Targeted therapies: Cetuximab dosing by rash\u2014is the scaling of EVEREST meaningful","volume":"9","author":"Stintzing","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0230","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1345\/aph.1M241","article-title":"Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"43","author":"Tan","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ad.2015.01.006_bib0235","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10637-014-0128-z","article-title":"The efficacy of Pistacia terebinthus soap in the treatment of cetuximab-induced skin toxicity","volume":"32","author":"Tastekin","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ad.2015.01.006_bib0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000342203","article-title":"Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor","volume":"225","author":"Shin","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2015.01.006_bib0245","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2015.01.006_bib0250","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1634\/theoncologist.2010-0082","article-title":"Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)","volume":"15","author":"Jatoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2015.01.006_bib0255","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0001-7310(06)73451-2","article-title":"Tratamiento de la erupci\u00f3n acneiforme por inhibidores del factor de crecimiento epid\u00e9rmico con tetraciclinas orales","volume":"97","author":"Fernandez-Guarino","year":"2006","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2015.01.006_bib0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000338865","article-title":"Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: An effective and convenient alternative to tetracyclines","volume":"224","author":"Nikolaou","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2015.01.006_bib0265","first-page":"77","article-title":"Acneiform eruptions induced by epidermal growth factor receptor inhibitors: Treatment with oral isotretinoin","volume":"90","author":"Requena","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2015.01.006_bib0270","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.144.7.949","article-title":"Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects","volume":"144","author":"Pomerantz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2015.01.006_bib0275","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0280","first-page":"1601","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ad.2015.01.006_bib0285","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clinical Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0290","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","year":"2013","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ad.2015.01.006_bib0295","first-page":"347","article-title":"[Cutaneous adverse effects predicting the efficacy of targeted antineoplastic therapies]","volume":"64","author":"Quatresooz","year":"2009","journal-title":"[Article in French]"},{"key":"10.1016\/j.ad.2015.01.006_bib0300","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00015550410024634","article-title":"Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor","volume":"84","author":"Zorzou","year":"2004","journal-title":"Acta Derm Venerol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731015000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:03:36Z","timestamp":1757552616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731015000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0001731015000654"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2015.01.006","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factores predictores de respuesta y revisi\u00f3n de la toxicidad cut\u00e1nea de cetuximab y panitumumab en 116 pacientes","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}